Wealth Enhancement Advisory Services
VKTX icon

Wealth Enhancement Advisory Services’s Viking Therapeutics VKTX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$493K Buy
12,691
+2,271
+22% +$73.4K ﹤0.01% 2701
2026
Q1 		$363K Sell
10,420
-5,174
-33% -$166K ﹤0.01% 2601
2025
Q4 		$504K Buy
15,594
+701
+5% +$24.8K ﹤0.01% 2475
2025
Q3 		$470K Buy
14,893
+5,900
+66% +$176K ﹤0.01% 2416
2025
Q2 		$254K Buy
+8,993
New +$237K ﹤0.01% 2784
2025
Q1 		– Sell
-10,117
Closed -$407K – 3174
2024
Q4 		$407K Sell
10,117
-15,598
-61% -$889K ﹤0.01% 2140
2024
Q3 		$1.63M Buy
25,715
+9,965
+63% +$585K ﹤0.01% 1157
2024
Q2 		$835K Buy
15,750
+8,344
+113% +$547K ﹤0.01% 1364
2024
Q1 		$607K Buy
+7,406
New +$330K ﹤0.01% 1470

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wealth Enhancement Advisory Services's VKTX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Viking Therapeutics (VKTX) stake by 22% in Q2 2026, buying an estimated $73.4K and bringing the position to 12,691 shares worth $493K. The position accounts for ﹤0.01% of the portfolio, ranked #2701.

Wealth Enhancement Advisory Services first reported a position in VKTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.63M in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 12,691 shares of Viking Therapeutics worth $493K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 2,271 Viking Therapeutics shares in Q2 2026, an estimated $73.4K.
  • Viking Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2701 holding.
  • Wealth Enhancement Advisory Services first reported a position in Viking Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Wealth Enhancement Advisory Services's Viking Therapeutics position peaked at $1.63M in Q3 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.